Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial
AbbVie
Kristian Reich; Melinda Gooderham; Diamant Thaçi; Jeffrey J Crowley; Caitriona Ryan; James G Krueger; Tsen-Fang Tsai; Mary Flack; Yihua Gu; David A Williams; Elizabeth H Z Thompson; Carle Paul